Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:KAYS OTCMKTS:NXEN OTCMKTS:OREXQ NASDAQ:VIRX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeKAYSKaya$0.01-11.8%$0.03$0.01▼$0.05$315K0.2513,288 shs3,429 shsNXENNexien Biopharma$0.00$0.01$0.00▼$0.05$99K-1.08533 shsN/AOREXQOrexigen Therapeutics$0.01+35.9%$0.01$0.00▼$0.16$100K4.9880,439 shs60,300 shsVIRXViracta Therapeutics$0.01$0.01$0.01▼$0.56$389K1.061.11 million shsN/AElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceKAYSKaya0.00%+0.62%-35.86%-58.72%-66.11%NXENNexien Biopharma0.00%-75.44%-75.44%-85.57%-91.95%OREXQOrexigen Therapeutics0.00%0.00%0.00%0.00%0.00%VIRXViracta Therapeutics0.00%0.00%0.00%-45.36%-96.59%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationKAYSKayaN/AN/AN/AN/AN/AN/AN/AN/ANXENNexien BiopharmaN/AN/AN/AN/AN/AN/AN/AN/AOREXQOrexigen TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AVIRXViracta Therapeutics1.7862 of 5 stars3.33.00.00.00.60.80.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceKAYSKaya 0.00N/AN/AN/ANXENNexien Biopharma 0.00N/AN/AN/AOREXQOrexigen Therapeutics 0.00N/AN/AN/AVIRXViracta Therapeutics 2.50Moderate Buy$1.1311,403.07% UpsideCurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookKAYSKaya$10K31.48N/AN/A($0.77) per share-0.02NXENNexien BiopharmaN/AN/AN/AN/A($0.01) per shareN/AOREXQOrexigen Therapeutics$33.71M0.00N/AN/AN/A∞VIRXViracta TherapeuticsN/AN/AN/AN/A$0.33 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateKAYSKaya-$2.08M-$0.08N/A∞N/AN/AN/A-1,044.25%N/ANXENNexien Biopharma-$240KN/A0.00∞N/AN/AN/A-4,015.59%N/AOREXQOrexigen Therapeutics-$24.52MN/A0.00∞N/AN/AN/AN/AN/AVIRXViracta Therapeutics-$51.06M-$1.10N/A∞N/AN/A-1,899.61%-114.21%N/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthKAYSKayaN/AN/AN/AN/AN/ANXENNexien BiopharmaN/AN/AN/AN/AN/AOREXQOrexigen TherapeuticsN/AN/AN/AN/AN/AVIRXViracta TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioKAYSKayaN/A0.010.01NXENNexien BiopharmaN/A0.020.02OREXQOrexigen TherapeuticsN/AN/AN/AVIRXViracta TherapeuticsN/A0.760.76Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipKAYSKayaN/ANXENNexien BiopharmaN/AOREXQOrexigen TherapeuticsN/AVIRXViracta Therapeutics31.37%Insider OwnershipCompanyInsider OwnershipKAYSKaya23.52%NXENNexien Biopharma30.60%OREXQOrexigen Therapeutics13.30%VIRXViracta Therapeutics10.69%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableKAYSKaya422.17 million16.96 millionNot OptionableNXENNexien Biopharma470.77 million49.12 millionNot OptionableOREXQOrexigen Therapeutics13218.89 millionN/ANot OptionableVIRXViracta Therapeutics2039.74 million35.50 millionNo DataOREXQ, NXEN, VIRX, and KAYS HeadlinesRecent News About These CompaniesHead-To-Head Analysis: Viracta Therapeutics (NASDAQ:VIRX) versus Zymeworks (NYSE:ZYME)August 17, 2025 | americanbankingnews.comCalif. biotech company once worth $476M lays off every remaining employeeFebruary 11, 2025 | msn.comViracta Therapeutics Terminates Employees & Winds Down OperationsFebruary 8, 2025 | contractpharma.comCViracta Therapeutics, Inc.: Viracta Therapeutics Announces Wind Down of OperationsFebruary 6, 2025 | finanznachrichten.deViracta Therapeutics Shuts Down Operations, Lays Off All StaffFebruary 6, 2025 | precisionmedicineonline.comPViracta Therapeutics terminates employees, to wind down operationsFebruary 6, 2025 | markets.businessinsider.comViracta Therapeutics to cease operations and seek alternativesFebruary 5, 2025 | msn.comViracta Therapeutics Winds Down Operations, Terminates EmployeesFebruary 5, 2025 | marketwatch.comViracta Therapeutics hits end of the line, laying off all workers and winding downFebruary 5, 2025 | fiercebiotech.comFViracta Therapeutics, Inc. Announces Employee Terminations and Wind Down of OperationsFebruary 5, 2025 | quiverquant.comQViracta Therapeutics Announces Wind Down of OperationsFebruary 5, 2025 | globenewswire.comWhy Did Viracta Therapeutics Inc (VIRX) Stock Tumble -46.67% to $0.08?February 4, 2025 | bovnews.comBVIRX stock plunges to 52-week low, touches $0.08February 3, 2025 | msn.comViracta Therapeutics to be delisted from NasdaqFebruary 3, 2025 | msn.comViracta Therapeutics strikes deal to avoid defaultJanuary 25, 2025 | msn.comViracta Therapeutics Inc (VIRX) Stock Trading RecapJanuary 10, 2025 | bovnews.comBVIRX’s Unexpected Surge: What’s Next?January 6, 2025 | bovnews.comBViracta Therapeutics Inc (VIRX) Stock Settles at $0.18: What’s Contributing to This Price Point?January 3, 2025 | bovnews.comBCash-strapped Viracta ends phase 2 study of lead cancer drug as it mulls remaining optionsJanuary 3, 2025 | fiercebiotech.comFLeerink Partners Issues Market Perform Rating for Viracta Therapeutics Inc (VIRX) StockDecember 30, 2024 | bovnews.comBNew MarketBeat Followers Over TimeOREXQ, NXEN, VIRX, and KAYS Company DescriptionsKaya OTCMKTS:KAYS$0.01 0.00 (-11.80%) As of 11:36 AM EasternKaya Holdings, Inc., a vertically integrated legal cannabis enterprise, engages in the operation of psychedelic treatment clinics and medical cannabis dispensaries primarily in the United States. It offers a range of cannabis products, including flower, oils, vape cartridges and cannabis infused confections, baked goods, and beverages. The company also operates retail outlets under the Kaya Shack brand name, as well as offers strain specific cannabis cigarettes under the Kaya Buddies name, and strains of cannabis under the Kaya Farms name. In addition, it is involved in the development of a psychedelic treatment center under The Sacred Mushroom name, that provides its guests access to psilocybin treatments, located in Portland, Oregon. The company was formerly known as Alternative Fuels America, Inc. and changed its name to Kaya Holdings, Inc. in April 2015. Kaya Holdings, Inc. is headquartered in Fort Lauderdale, Florida.Nexien Biopharma OTCMKTS:NXEN$0.0014 0.00 (0.00%) As of 08/21/2025Nexien BioPharma, Inc. focuses on the formulation, development, and commercialization of cannabinoid-based pharmaceuticals, drug delivery systems, and related technologies for diseases, disorders, and medical conditions. The company was formerly known as Intiva BioPharma Inc. and changed its name to Nexien BioPharma, Inc. in September 2018. Nexien BioPharma, Inc. is based in Glendale, Colorado.Orexigen Therapeutics OTCMKTS:OREXQ$0.0053 +0.00 (+35.90%) As of 05/31/2019Orexigen Therapeutics, Inc., a biopharmaceutical company, focuses on the development of pharmaceutical products primarily in the United States, Europe, and South Korea. It offers Contrave for the treatment of obesity. The company also offers Contrave under the Mysimba brand name. Orexigen Therapeutics, Inc. was founded in 2002 and is headquartered in La Jolla, California. On March 12, 2018, Orexigen Therapeutics, Inc., filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.Viracta Therapeutics NASDAQ:VIRX$0.0098 0.00 (0.00%) As of 07/25/2025Viracta Therapeutics, Inc., a clinical-stage precision oncology company, focuses on the treatment and prevention of virus-associated cancers that impact patients worldwide. Its lead product candidate is Nana-val, an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir. The company's Nana-val is in various ongoing clinical trials, including NAVAL-1, an open-label Phase 2 basket trial for the treatment of multiple subtypes of relapsed/refractory Epstein-Barr virus-positive (EBV+) lymphoma, as well as an open-label Phase 1b/2 trial for the treatment of EBV+ recurrent or metastatic nasopharyngeal carcinoma and other EBV+ solid tumors. Its product pipeline also includes vecabrutinib, a clinical-stage product candidate; and VRx-510, a preclinical product candidate. The company is headquartered in Cardiff, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas After Earnings Miss, Walmart Is Still a Top Consumer Staples Play Should You Join Buffett and Invest in Constellation Brands? Can Identity Security Fuel CrowdStrike’s Next Growth Phase? 3 Robotics Stocks at the Heart of the Robotics Revolution Analog Devices and an AI-Driven Semiconductor Supercycle Shopify’s Risk-Reward Profile Is Suddenly Red Hot 3 Reasons Salesforce Is a Bargain Right Now Broadcom Named in Apple’s $100B U.S. Investment Plan Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access